Rmpl Pharma LLP — Rituximab Exporter Profile
Indian Pharmaceutical Exporter · #10 for Rituximab · $92.7K export value · DGFT Verified
Rmpl Pharma LLP is the #10 Indian exporter of Rituximab with $92.7K in export value and 55 verified shipments. Rmpl Pharma LLP holds a 0.5% market share in Rituximab exports across 9 countries. The company exports 13 pharmaceutical products worth $438.6K across 3 therapeutic categories.
Rmpl Pharma LLP — Rituximab Export Profile: Buyers & Destinations
Where Does Rmpl Pharma LLP Export Rituximab?
| Country | Value | Shipments | Share |
|---|---|---|---|
| LEBANON | $60.7K | 22 | 65.4% |
| KENYA | $12.9K | 9 | 14.0% |
| TANZANIA | $6.9K | 5 | 7.5% |
| TURKEY | $3.8K | 7 | 4.1% |
| IRAQ | $3.7K | 3 | 4.0% |
| UNITED ARAB EMIRATES | $2.1K | 1 | 2.3% |
| UGANDA | $1.3K | 4 | 1.4% |
| TOGO | $769 | 3 | 0.8% |
| DJIBOUTI | $427 | 1 | 0.5% |
Rmpl Pharma LLP exports Rituximab to 9 countries. The largest destination is LEBANON accounting for 65.4% of Rmpl Pharma LLP's Rituximab shipments, followed by KENYA (14.0%) and TANZANIA (7.5%). These destinations reflect Rmpl Pharma LLP's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Rituximab from Rmpl Pharma LLP?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF INVOICE | LEBANON | $62.2K | 37 |
| TO THE ORDER OF INVOICE RAISED TO | UGANDA | $25.1K | 13 |
| INVOICE RAISED TO | UGANDA | $728 | 2 |
Rmpl Pharma LLP supplies Rituximab to 3 buyers globally. The largest buyer is TO THE ORDER OF INVOICE (LEBANON), followed by TO THE ORDER OF INVOICE RAISED TO (UGANDA) and INVOICE RAISED TO (UGANDA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Rituximab Export Value and How Much Does Rmpl Pharma LLP Contribute?
India exported $9.4M worth of Rituximab through 1,215 shipments from 164 suppliers to 104 countries, serving 292 buyers globally. Rmpl Pharma LLP contributes $92.7K to this total, accounting for 0.5% of India's Rituximab exports. Rmpl Pharma LLP ships Rituximab to 9 countries through 3 buyers.
What Is the Average Shipment Value for Rmpl Pharma LLP's Rituximab Exports?
Rmpl Pharma LLP's average Rituximab shipment value is $1.7K per consignment, based on 55 shipments totaling $92.7K. The largest destination is LEBANON (65.4% of Rmpl Pharma LLP's Rituximab exports).
How Does Rmpl Pharma LLP Compare to Other Indian Rituximab Exporters?
Rmpl Pharma LLP ranks #10 among 164 Indian Rituximab exporters with a 0.5% market share. The top 3 exporters are RELIANCE LIFE SCIENCES PRIVATE LIMITED ($4.1M), DR.REDDY'S LABORATORIES LTD ($3.2M), DR REDDYS LABORATORIES LIMITED ($550.0K). Rmpl Pharma LLP processed 55 shipments to 9 destination countries.
What Rituximab Formulations Does Rmpl Pharma LLP Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| MABALL 500MG INJ. (VIAL) (RITUXIMAB 500MG/50ML) | $23.5K | 6 |
| RITUXIREL RN 500MG (VIAL)(RITUXIMAB 500MG/5ML) (150 VIALS)VLS | $11.2K | 1 |
| MABALL 500MG/50ML INJ.(VIAL) (RITUXIMABINJECTION) (38 VIALS) | $9.4K | 3 |
| MABALL 500MG INJ. (VIAL)(RITUXIMAB 500MG/50ML) (75 VIALS) | $5.3K | 1 |
| MABALL 500MG 50ML INJ VIAL RITUXIMABINJ 75 VIALS | $5.0K | 1 |
| RITUXIREL RN 500MG(VIAL) (RITUXIMAB 500MG/50ML) (50 VIALS) | $3.7K | 1 |
| MABALL 500MG INJ. (VIAL) (RITUXIMAB 500MG/50ML) (50 VIALS) | $3.2K | 1 |
| MABALL 500MG/50ML INJ.(VIAL) (RITUXIMABINJECTION) (12 VIALS) | $3.0K | 3 |
| MABALL 500MG INJ. (37 VIAL) (RITUXIMAB 500MG/50ML) | $2.9K | 1 |
| ENFIERA 500MG INJ (VIAL) (RITUXIMAB 500M | $2.8K | 4 |
Rmpl Pharma LLP exports 38 distinct Rituximab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MABALL 500MG INJ. (VIAL) (RITUXIMAB 500MG/50ML) with 6 shipments worth $23.5K.
How Does Rmpl Pharma LLP Compare to Nearest Rituximab Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | J.A. UNITED EXPORTS PRIVATE LIMITED | $122.3K | 20 | 4 | $6.1K |
| 9 | R.S. SURGIPHARM PRIVATE LIMITED | $118.2K | 63 | 2 | $1.9K |
| 10 | RMPL PHARMA LLP ★ | $92.7K | 55 | 9 | $1.7K |
| 11 | PNT PHARMA | $86.7K | 12 | 1 | $7.2K |
| 12 | SANSKRUTI PHARMA | $71.6K | 62 | 3 | $1.2K |
Rmpl Pharma LLP ranks #10 among 164 Indian Rituximab exporters. Average shipment value of $1.7K compared to the market average of $57.4K. The closest competitors by value are J.A. UNITED EXPORTS PRIVATE LIMITED and R.S. SURGIPHARM PRIVATE LIMITED.
Which Indian Ports Ship Rituximab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 389 | 32.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 325 | 26.7% |
| Bombay Air | 85 | 7.0% |
| Bombay Air Cargo | 58 | 4.8% |
| HYDERABAD ACC (INHYD4) | 46 | 3.8% |
| DELHI AIR CARGO ACC (INDEL4) | 45 | 3.7% |
| DELHI AIR | 35 | 2.9% |
| AHEMDABAD AIR | 26 | 2.1% |
What Other Advanced Oncology Products Does Rmpl Pharma LLP Export?
Rmpl Pharma LLP also exports these advanced oncology products. Each links to the detailed product page.
About Rmpl Pharma LLP
Rmpl Pharma LLP exports 13 products worth $438.6K. Beyond Rituximab, top products include Lenalidomide, Daratumumab, Cladribine, Ibrutinib, Dacarbazine. View the complete Rmpl Pharma LLP profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Rituximab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Rituximab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Rmpl Pharma LLP matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 55 individual customs records matching Rmpl Pharma LLP exporting Rituximab, covering 38 formulations to 9 countries via 3 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 104+ countries, 292+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Rituximab Export Data from Rmpl Pharma LLP
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Rmpl Pharma LLP's Rituximab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Rmpl Pharma LLP
Full Company Profile →
13 products · $438.6K total trade · 3 categories
Rituximab Stats
Company Overview
Top Products by Rmpl Pharma LLP
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Rmpl Pharma LLP.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Rituximab. For current shipment-level data, contact TransData Nexus.